CRISPR Therapeutics Corp (CRSP) Business Payback Period

Symbol and logo of brand CRISPR (CRSP)

High R&D expenses and uncertainty regarding insurance reimbursements create volatility, which, while tracking the current P/E ratio of CRISPR Therapeutics AG (CRSP) on GURU.Markets, we observe in the price action where the -8.50 mark serves as a key metric. CRISPR Therapeutics AG (CRSP) maintains stability through its own gene synthesis plants and close partnerships with global pharma behemoths to jointly develop innovations.

CRSP (crisprtx.com) Price to Earnings Ratio history from 07/04/2022 to 11/18/2026

Analytical breakdowns for CRISPR Therapeutics Corp (CRSP)

- market value and analyst target forecast:
Summary company analysis:CRISPR Therapeutics - CRSP
Flagship merchandise of CRISPR Therapeutics Inc

CRISPR Therapeutics AG (CRSP) transition toward the commercialization of gene therapies and the stabilization of cash flows create a foundation for shifting from capital burn to operating profit. Analyzing the P/E valuation multiple with a value of -8.50, an investor assesses the ratio of the business's market value to its actual earnings, which allows for determining the extent of the premium paid for future growth and evaluating the long-term sustainability of the asset.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|WGS: Price to Earnings Ratio|Market Cap to Net Income Ratio Ultragenyx (RARE)|BEAM: P/E Multiple|Sarepta Therapeutics, Inc. (SRPT) - P/E Multiple|TWST (twistbioscience.com) - P/E Multiple|10x Genomics, Inc. (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics, Inc.)|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio